跳转至内容
Merck
CN

S-003

Supelco

R(-)-Selegiline solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

别名:

(-)-Deprenyl

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C13H17N
CAS号:
分子量:
187.28
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

certified reference material

形式

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

格式

single component solution

储存温度

−20°C

SMILES字符串

C[C@@H](N(CC#C)C)CC1=CC=CC=C1

InChI

1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1

InChI key

MEZLKOACVSPNER-GFCCVEGCSA-N

基因信息

human ... MAOB(4129)

一般描述

A Certified Spiking Solution® suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, or urine drug testing. Selegiline is an antidepressant, which belongs to the phenethylamine class of drugs. It is sold under the trade names Anipryl®, Emsam®, and Zelapar® for treatment of Parkinson′s disease, depression, and senile dementia.

法律信息

Anipryl is a registered trademark of Deprenyl Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Emsam is a registered trademark of Somerset Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zelapar is a registered trademark of Valeant Pharmaceuticals North America LLC

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes

WGK

WGK 2

闪点(°F)

49.5 °F

闪点(°C)

9.7 °C

法规信息

危险化学品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Keiko Inaba-Hasegawa et al.
Journal of neural transmission (Vienna, Austria : 1996), 120(3), 435-444 (2012-09-13)
Type B monoamine oxidase (MAO-B) is proposed to be involved in the pathogenesis of neurodegenerative disorders, such as Parkinson's disease, through oxidative stress and synthesis of neurotoxins. MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neuronal cells by direct intervention in
Joanna M Krysiak et al.
Angewandte Chemie (International ed. in English), 51(28), 7035-7040 (2012-06-13)
High profile: new activity-based protein profiling (ABPP) probes have been designed that target exclusively monoamine oxidases A and B within living cells (see picture; FAD=flavin adenine dinucleotide, FMN=flavin monodinucleotide). With these probes it could be shown that the MAO inhibitor
Chi-Un Pae et al.
The Journal of clinical psychiatry, 73(5), 661-668 (2012-06-16)
The objective of this analysis is to present the safety profile of selegiline transdermal system (STS) in clinical practice after US Food and Drug Administration approval by analyzing reported postmarketing adverse events (AEs). Deidentified data were obtained on AEs, regardless
Jorge A Zavala et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 19(9), 1298-1299 (2012-06-23)
Pramipexole is a non-ergot dopamine agonist that is used frequently as a single therapy or in combination for the management of Parkinson's disease. Common side effects are daytime drowsiness, hypotension, hallucinations and compulsive behaviour. We describe a patient who developed
Dhaval R Kalaria et al.
International journal of pharmaceutics, 438(1-2), 202-208 (2012-09-08)
The objective was to investigate the anodal iontophoresis of the MAO-B inhibitors rasagiline (RAS) and selegiline (SEL) across porcine and human skin in vitro. Passive delivery of RAS and SEL from aqueous solution was minimal; however, increasing current density from

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门